How ‘Pay to Delay’ Impacts Self-Insureds and Other Pharmaceutical Payers

Share!

Risk & Insurance - Sep 16, 2020

Two parallel courses of litigation, one in California and one in Illinois, have thrust the long-running dispute over the high cost of patented pharmaceuticals to the fore. Advertisement They have also reinforced how complex the issues are. Late in July, the U.S. Ninth Circuit Court upheld Califo...

Read Full Article

Recommended Articles

Insurers Face the Same Cyber Threats They Underwrite — and Gaps Remain

Posted: Apr 16, 2026

A joint report from the Insurance Information Institute and Fenix24 found that insurers, despite set...

Jeff Green Discusses Innovation, Challenges and Leading the Charge in Public Risk Management

Posted: Apr 16, 2026

Jeff Green, the risk manager for Larimer County, Colo. Recounts his years in the profession and why...

Psychological Safety on Jobsites Directly Reduces Incidents and Turnover, Analysis Shows

Posted: Apr 15, 2026

Poor communication contributes to nearly 70% of workplace incidents, underscoring the business case...